Dr. Matthew Weinstock joins Novel Biotechnology Inc as CTO

Dr. Matthew Weinstock joins Novel Biotechnology Inc as CTO

Matthew Weinstock, PhD, is an accomplished biotech executive with experience working in both start-up and growth-stage companies, having built and led a scientific organization with close to 200 employees.

His technical expertise spans protein engineering, drug discovery, advanced biomanufacturing, and synthetic biology. His efforts have led to technologies that have been successfully commercialized or have resulted in technology development partnerships with top-10 pharma companies.

Prior to joining Novel Biotechnologies, Dr. Weinstock served as Chief Technology Officer at Absci Corporation, a biotech company developing advanced technologies for drug discovery and biomanufacturing. Prior to Absci, Dr. Weinstock was employed at the synthetic biology firm Synthetic Genomics, Inc., where he worked in the R&D group of Dr. Daniel Gibson.

Dr. Weinstock has a PhD in Biochemistry from the University of Utah School of Medicine where he was part of a group focused on the advancement of mirror-image display technologies to discover D-peptide therapeutics against emerging infectious diseases.

No Comments

Sorry, the comment form is closed at this time.